×
About 6,280 results

ALLMedicine™ Candidiasis Center

Research & Reviews  1,838 results

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Jan 19th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Novel risk factors associated with common vaginal infections: a nationwide primary heal...
https://doi.org/10.1016/j.ijid.2022.01.021
International Journal of Infectious Diseases : IJID : Off... Jansåker F, Frimodt-Møller N et. al.

Jan 18th, 2022 - To estimate the association between potential risk factors and common vaginal infections, using nationwide primary healthcare and other national register. An open cohort study consisting of 2 357 711 women aged 15-50 years (2001-2018) was conducte...

IL-33 Coordinates Innate Defense to Systemic Candida albicans Infection by Regulating I...
https://doi.org/10.4049/jimmunol.2100495
Journal of Immunology (Baltimore, Md. : 1950); Nguyen NZN, Tran VG et. al.

Jan 14th, 2022 - Invasive candidiasis has high mortality rates in immunocompromised patients, causing serious health problems. In mouse models, innate immunity protects the host by rapidly mobilizing a variety of resistance and tolerance mechanisms to systemic Can...

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
https://clinicaltrials.gov/ct2/show/NCT03562156

Jan 13th, 2022 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

Development, optimization, and evaluation of a nanostructured lipid carrier of sesame o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757592
Drug Delivery; Hosny KM, Sindi AM et. al.

Jan 12th, 2022 - Candida albicans is the fungus responsible for oral candidiasis, a prevalent disease. The development of antifungal-based delivery systems has always been a major challenge for researchers. This study was designed to develop a nanostructured lipid...

see more →

Guidelines  8 results

British HIV Association/British Infection Association guidelines on the management of o...
https://doi.org/10.1111/hiv.12806
HIV Medicine 7 References; Dockrell DH, O’Shea D et. al.

Nov 2nd, 2019 - British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.|2019|Dockrell DH,O’Shea D,Cartledge JD,Freedman AR,|diagnosis,dru...

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727169
American Journal of Respiratory and Critical Care Medicine; Hage CA, Carmona EM et. al.

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Managing xerostomia and salivary gland hypofunction: executive summary of a report from...
https://doi.org/10.14219/jada.2014.44
Journal of the American Dental Association (1939); Plemons JM, Al-Hashimi I et. al.

Aug 2nd, 2014 - Xerostomia, also known as "dry mouth," is a common but frequently overlooked condition that is typically associated with salivary gland hypofunction, which is the objective measurement of reduced salivary flow. Patients with dry mouth exhibit symp...

Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.
https://doi.org/10.1007/s00134-013-3134-2
Intensive Care Medicine; Montravers P, Dupont H et. al.

Oct 25th, 2013 - Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.|2013|Montravers P,Dupont H,Eggimann P,|therapeutic use,drug effects,drug therapy,microbiology,drug therapy,microbiology,

see more →

Drugs  402 results see all →

Clinicaltrials.gov  80 results

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Jan 19th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
https://clinicaltrials.gov/ct2/show/NCT03562156

Jan 13th, 2022 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

Suppression Of Bacterial Vaginosis (BV) [SUBVert]
https://clinicaltrials.gov/ct2/show/NCT03930745

Jan 10th, 2022 - This is a Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure (TOC) visit...

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
https://clinicaltrials.gov/ct2/show/NCT05178862

Jan 5th, 2022 - This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin follo...

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
https://clinicaltrials.gov/ct2/show/NCT03561701

Dec 20th, 2021 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

see more →

News  180 results

Miltefosine Granted Orphan Drug Approval for Invasive Candidiasis
https://www.medscape.com/viewarticle/962804

Nov 12th, 2021 - The US Food and Drug Administration (FDA) has granted orphan drug designation approval of miltefosine (Profounda, Inc) for the treatment of invasive candidiasis. This condition includes the potentially life-threatening candidemia, which is among t...

Oteseconazole Promising for Recurrent Yeast Infections
https://www.medscape.com/viewarticle/960068

Sep 30th, 2021 - A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast infections (vulvovaginal candidiasis [VVC]) and in p...

Expert shares vulvovaginal candidiasis treatment pearls
https://www.mdedge.com/dermatology/article/245609/infectious-diseases/expert-shares-vulvovaginal-candidiasis-treatment
Doug Brunk

Sep 2nd, 2021 - For patients who present with pesky vulvovaginal candidiasis, consider a course of ibrexafungerp, a first-in-class oral triterpenoid antifungal drug that was approved in June 2021, Aruna Venkatesan, MD, recommends. Dr.

Bimekizumab Approved in Europe for Psoriasis Treatment
https://www.medscape.com/viewarticle/957194

Aug 25th, 2021 - Bimekizumab has been approved by the European Commission for the treatment of moderate to severe plaque psoriasis in adults, according to a statement from the manufacturer. Bimekizumab (Bimzelx), a humanized IgG1 monoclonal antibody, is the first ...

Secnidazole Gets FDA Nod for Trichomoniasis
https://www.medscape.com/viewarticle/954207

Jul 2nd, 2021 - The Food and Drug Administration has expanded the approval of secnidazole to include treatment of trichomoniasis in adults, according to a statement from manufacturer Lupin Pharmaceuticals. Trichomoniasis vaginalis is a common, nonviral, curable s...

see more →

Patient Education  4 results see all →